About the Phase 1/2 Study 2102-HEM-101 of Olutasidenib in IDH1-Mutated AML
Jorge E. Cortes, MD, provides an overview of the background and findings of the phase 1/2 Study 2102-HEM-101 of olutasidenib in patients with relapsed/refractory IDH1-mutated acute myeloid leukemia.
Exploring Current Therapeutic Options and Treatment Selection in CML
Jorge E. Cortes, MD, discusses the current therapies available to treat patients with chronic myeloid leukemia and how to choose between them when there is similar efficacy.
CPX-351 Demonstrates Long-Term Survival Benefits in Patients With AML
Jorge E. Cortes, MD, discusses the 5-year overall survival results of CPX-351 versus 7+3 in patients with newly diagnosed high-risk or secondary acute myeloid leukemia.
The Role of Ruxolitinib in Myeloproliferative Neoplasms
Jorge E. Cortes, MD, explains how ruxolitinib is used to treat various myeloproliferative neoplasms and which patients require other therapies.
